Neratinib for HER2-positive breast cancer with an overlooked option | Molecular Medicine | Full Text
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
FP14.15 Neratinib-Based Combination Therapy in HER2-Mutant Lung Adenocarcinomas: Findings from two International Phase 2 Studies - Journal of Thoracic Oncology
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | The Motley Fool
Neratinib | 99.94%(HPLC) | In Stock | HER2 inhibitor
Puma Biotechnology
Puma Biotech Gets Favorable FDA Vote On Neratinib - Puma Biotechnology (NASDAQ:PBYI) - Benzinga
Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium | Business Wire
Puma Biotechnology reports interim SUMMIT results for neratinib | Drug Discovery News
A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories - TheStreet
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | Fierce Pharma
Neratinib-based therapy in patients with metastatic HER2-positive breast cancer from Asia | Future Oncology
Puma Biotechnology Surging
Nerlynx: Package Insert - Drugs.com
Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer - ScienceDirect
Puma Biotechnology Presents Updated Results from the Phase II SUMMIT Trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 | Business Wire
NERATINIB, HKI 272, ..Puma presents positive results from phase II trial of its investigational drug PB272 | New Drug Approvals
Neratinib Plus Capecitabine Approved for HER2-Positive Metastatic Breast Cancer
Puma Biotechnology: Who Are They? What Happened? And, Where Are They Going? (NASDAQ:PBYI) | Seeking Alpha
Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU | Clinical Drug Investigation
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers | Nature Communications
